Bob M. Moore II is a medicinal chemist with over 15 years of experience in the design, synthesis, and pre-clinical evaluation of cannabinoid based therapeutic agents. He has developed eight novel classes of cannabinoid receptor 1 and 2 (CB1 and CB2) ligands resulting in 19 U.S. patents for composition of matter and methods of use. The current focus of Dr. Moore’s research is the development of CB2 inverse agonists to treat neuroinflammation associated with microglia activation.